Real-world data on nivolumab treatment of non-small cell lung cancer
Author:
Affiliation:
1. Department of Oncology, Oslo University Hospital The Norwegian Radium Hospital, Oslo, Norway;
2. Department of Cancer Genetics, Oslo University Hospital – The Norwegian Radium Hospital, Oslo, Norway
Funder
Kreftforeningen
South-Eastern Norway Regional Health Authority
Publisher
Informa UK Limited
Subject
Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2016.1253865
Reference8 articles.
1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
5. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Comprehensive evaluation of PD-1 inhibitors marketed in China based on a Quick Guideline for drug evaluation and selection in Chinese Medical Institutions (second edition);Intelligent Pharmacy;2024-08
2. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study;Current Medical Research and Opinion;2024-06-22
3. Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study;Cancer Medicine;2023-11-21
4. Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting;The Oncologist;2023-08-21
5. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors;International Immunopharmacology;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3